Was :
$81
Today :
$45
Was :
$99
Today :
$55
Was :
$117
Today :
$65
Why Should You Prepare For Your Certified Clinical Data Manager With MyCertsHub?
At MyCertsHub, we go beyond standard study material. Our platform provides authentic SCDM CCDM Exam Dumps, detailed exam guides, and reliable practice exams that mirror the actual Certified Clinical Data Manager test. Whether you’re targeting SCDM certifications or expanding your professional portfolio, MyCertsHub gives you the tools to succeed on your first attempt.
Verified CCDM Exam Dumps
Every set of exam dumps is carefully reviewed by certified experts to ensure accuracy. For the CCDM Certified Clinical Data Manager , you’ll receive updated practice questions designed to reflect real-world exam conditions. This approach saves time, builds confidence, and focuses your preparation on the most important exam areas.
Realistic Test Prep For The CCDM
You can instantly access downloadable PDFs of CCDM practice exams with MyCertsHub. These include authentic practice questions paired with explanations, making our exam guide a complete preparation tool. By testing yourself before exam day, you’ll walk into the SCDM Exam with confidence.
Smart Learning With Exam Guides
Our structured CCDM exam guide focuses on the Certified Clinical Data Manager's core topics and question patterns. You will be able to concentrate on what really matters for passing the test rather than wasting time on irrelevant content. Pass the CCDM Exam – Guaranteed
We Offer A 100% Money-Back Guarantee On Our Products.
After using MyCertsHub's exam dumps to prepare for the Certified Clinical Data Manager exam, we will issue a full refund. That’s how confident we are in the effectiveness of our study resources.
Try Before You Buy – Free Demo
Still undecided? See for yourself how MyCertsHub has helped thousands of candidates achieve success by downloading a free demo of the CCDM exam dumps.
MyCertsHub – Your Trusted Partner For SCDM Exams
Whether you’re preparing for Certified Clinical Data Manager or any other professional credential, MyCertsHub provides everything you need: exam dumps, practice exams, practice questions, and exam guides. Passing your CCDM exam has never been easier thanks to our tried-and-true resources.
SCDM CCDM Sample Question Answers
Question # 1
An organization has completed a study and wants to submit the data to the FDA using CDISC SDTM.
Which of the following must be done?
A. Map and transform the study data to SDTM B. Re-enter the data into an SDTM compliant system C. Provide a letter of intent to use SDTM to the FDA D. SDTM cannot be used in this situation
Answer: A Explanation:
To submit study data to the FDA in CDISC SDTM format, the sponsor must map and transform the
collected data from the studys operational database (e.g., EDC) into SDTM-compliant domains.
According to GCDMP (Chapter: Standards and Data Integration) and CDISC SDTM Implementation
Guide, this process includes:
Mapping raw data elements from the clinical database to SDTM domains (e.g., DM, AE, VS).
Transforming data to comply with SDTM structural and naming conventions.
Validating the output using CDISC compliance tools (e.g., Pinnacle 21).
Re-entering data (B) is unnecessary, and a letter of intent (C) is not required. SDTM is explicitly
accepted by FDA for both retrospective and prospective submissions, so (D) is incorrect.
Thus, option A is correct ” map and transform existing data to SDTM format for regulatory
submission.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Standards and Data Integration, Section 5.3 “ Data Transformation and
CDISC Mapping CDISC SDTM Implementation Guide, Version 3.4 “ Data Conversion and Submission Requirements
FDA Study Data Technical Conformance Guide, Section 2.2 “ SDTM Mapping and Validation
Question # 2
A study uses commercially available activity monitors and collects data for each patient weekly by
selecting and downloading the data from the manufacturer's website. There are 100 patients in the study and it takes the Data Manager 20 minutes per file to download, import, and process the dat
a. Assuming that the distribution of work is uniform over the six-month trial, how many Data
Managers are needed for the activity data alone?
A. Ten percent of a Data Manager per month B. Fifty percent of a Data Manager per month C. Two Data Managers per month D. One Data Manager per month
Answer: D Explanation:
This question tests workload estimation and resource planning, which are fundamental
competencies outlined in the Good Clinical Data Management Practices (GCDMP, Chapter on Project
Management in Data Management). The task is to determine the Data Manager effort required
based on the frequency and duration of data collection and processing activities.
Lets calculate step by step:
Number of patients: 100
Frequency: Weekly (once per week)
Duration: 6 months ≈ 26 weeks
Time per file: 20 minutes
Total time per week:
100 patients × 20 minutes = 2,000 minutes per week
= 2,000 Ã? 60 = 33.3 hours per week
Total hours over 6 months:
33.3 hours/week × 26 weeks = 866 hours total
A full-time Data Manager typically works ~160 hours per month, so over six months:
160 × 6 = 960 hours total full-time capacity.
Therefore, the workload of 866 hours is approximately equivalent to one full-time Data Manager
working across the six-month period:
866 � 960 ≈ 0.9 FTE (Full-Time Equivalent).
This aligns most closely with Option D: One Data Manager per month (i.e., a full-time resource is
required throughout the duration of the trial).
According to the GCDMP Project Management chapter, accurate resource estimation is critical in
ensuring data management timelines are met without overloading staff or compromising data
quality. The estimation process must consider not just the raw data download time but also
associated data processing, verification, and upload into the clinical database.
Other options underestimate the effort significantly:
A (10%) and B (50%) do not account for cumulative weekly workload across multiple patients. C (Two Data Managers) overestimates, as one Data Manager working full-time can manage the load
efficiently.
Therefore, Option D is correct ” approximately one full-time Data Manager (1.0 FTE) is required for
the activity data alone during the six-month trial.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP),
Chapter: Project Management in Data Management, Section 5.3 “ Workload Estimation and
Resource Allocation
SCDM GCDMP, Chapter: Data Handling and Processing “ Effort Estimation for Repetitive Data Tasks
ICH E6 (R2) Good Clinical Practice, Section 5.1 “ Quality Management and Resource Planning
FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 4.3 “ Operational
Considerations for Data Management Activities
Question # 3
Before the EDC system used for the trial is upgraded, what should be the data manager's first task?
A. Notify the sites of the upgrade B. Update the user manual C. Assess the impact on the data D. Redesign the eCRF
Answer: C Explanation:
Before implementing an EDC system upgrade, the first task of the Data Manager is to assess the
impact on the data.
According to the GCDMP (Chapter: Electronic Data Capture Systems) and FDA 21 CFR Part 11, any
system upgrade must undergo impact assessment to determine how the change might affect data
integrity, functionality, validation, and ongoing study operations. This assessment ensures that no
data are lost, corrupted, or rendered inconsistent during or after the upgrade.
The Data Manager should evaluate:
Potential effects on existing data, edit checks, and reports,
System functionality impacting current workflows, and
Any revalidation requirements.
Only after the impact is understood should the Data Manager proceed to communicate with sites
(option A), update documentation (option B), or modify CRFs if required (option D).
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture
Systems, Section 7.3 “ System Upgrades and Change Control
FDA 21 CFR Part 11 “ Change Control and Validation Requirements
ICH E6 (R2) Good Clinical Practice, Section 5.5.3 “ Change Impact on Data Integrity and System
Validation
Question # 4
A Data Manager is establishing a timeline for database lock for a 100-person study where the data
have been maintained almost all clean throughout the study. All data from external labs have been
received and reconciled. Which is the best estimate of the amount of time needed to lock the
database after Last Patient Last Visit?
A. A few hours B. A few days C. A few months D. A few weeks
Answer: B Explanation:
For a well-maintained 100-subject study with ongoing data cleaning and completed reconciliations,
the database lock process typically takes a few days after the Last Patient Last Visit (LPLV).
According to the GCDMP (Chapter: Database Lock and Archiving), the duration of the lock process
depends on the level of data cleanliness at LPLV. If the study team has conducted continuous data
cleaning, query resolution, and external data reconciliation throughout the trial, then the final lock
steps (e.g., final data review, documentation, and approvals) can be completed in 2“5 days.
However, if significant cleaning or reconciliation remains outstanding, lock may take several weeks.
Since the question states that data are œmaintained almost all clean, Option B “ a few days “ is the
appropriate estimate.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Lock and Archiving, Section: Section 6.2 “ Database Lock Preparation and Timelines
ICH E6 (R2) Good Clinical Practice, Section 5.5.3 “ Data Quality and Lock Procedures
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations “ Data Lock and
Archiving Procedures
Question # 5
Data characterizing the safety profile of a drug are collected to provide information for which of the
following?
A. Survival curves B. Efficacy meta-analyses C. Product labeling D. Quality of life calculations
Answer: C Explanation:
Safety data collected during a clinical trial are used primarily to support product labeling, ensuring
accurate communication of a drugs risks, contraindications, and adverse reactions to healthcare
providers and patients.
According to the GCDMP (Chapter: Safety Data Handling and Reconciliation) and ICH E2A/E2F guidelines, all adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities are
analyzed and summarized to define the safety profile of an investigational product. These data form
the basis for regulatory submissions such as the Clinical Study Report (CSR) and product labeling
(e.g., prescribing information), as required by the FDA and other regulatory authorities.
While safety data may contribute indirectly to analyses such as survival curves (option A) or quality
of life metrics (option D), their primary regulatory function is to inform product labeling and postmarketing
surveillance documentation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Safety Data Handling and
Reconciliation, Section 4.3 “ Use of Safety Data in Regulatory Submissions
ICH E2A “ Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
FDA Guidance for Industry: Adverse Event Reporting and Labeling Requirements
Question # 6
A study team member states that data entry can be done by clerical personnel at sites. Which are
important considerations?
A. It is possible that clerical personnel could be hired by sites because data entry requires little training and use of clerical personnel would reduce burden on sites B. Historically in clinical research site study coordinator roles have been filled by people with clinical or clinical research experience C. Data entry at sites requires study-specific training on how to use the EDC system to enter data and respond to data discrepancies identified by the system D. The person at the sites who enters the data usually also understands which data in the medical record are needed for the study, where to find them and which value to choose
Answer: C Explanation:
Although clerical staff can technically perform data entry, data entry in clinical research requires
study-specific training, particularly in the use of the Electronic Data Capture (EDC) system and
understanding data discrepancy resolution procedures.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data
Collection) and ICH E6 (R2), individuals responsible for data entry at clinical sites must be qualified by
education, training, and experience. This includes understanding how to navigate the EDC system,
enter data according to CRF Completion Guidelines, and appropriately respond to queries or systemgenerated
edit checks.
Untrained clerical personnel may inadvertently introduce errors, violate Good Clinical Practice (GCP)
standards, or fail to recognize protocol-relevant data. Therefore, the Data Manager must ensure that
site users receive study-specific and system training before gaining access to the EDC environment.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection,
Section: Section 5.2 “ Investigator Site Training and Data Entry Requirements
ICH E6 (R2) Good Clinical Practice, Section 4.1.5 “ Qualified Personnel and Training Requirements
FDA 21 CFR Part 11 “ User Access and Training Provisions for Electronic Records
Question # 7
Which of the following processes is the most likely to remain in a study that utilizes electronic data capture?
A. Tracking case report forms B. Updating the in-house database C. Resolving queries D. Retrieving case report forms
Answer: C Explanation: In studies utilizing Electronic Data Capture (EDC) systems, many traditional paper-based processes such as tracking and retrieving CRFs are eliminated or automated. However, query management and resolution remain essential because discrepancies, missing data, and protocol deviations still require clarification and correction, regardless of the data collection medium. According to the GCDMP (Chapter: Data Validation and Cleaning), data queries are generated automatically or manually when inconsistencies are detected by edit checks. Sites must still respond to these queries electronically to ensure the integrity and completeness of data. A and D are obsolete with EDC (no physical CRFs). B refers to manual data entry updates, which are replaced by direct EDC entry. C (Resolving queries) continues as a key part of the data management workflow, even in fully electronic environments. Thus, option C is correct. Reference (CCDM-Verified Sources): SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 5.4 “ Query Generation and Resolution in EDC Systems ICH E6(R2) GCP, Section 5.5.3 “ Data Review and Query Resolution Requirements FDA 21 CFR Part 11 “ Electronic Records: Audit Trails and Query Documentation
Question # 8
Which method would best identify clinical chemistry lab data affected by a blood draw taken distal to
a saline infusion?
A. Abnormally high sodium values in a dataset B. Lab values from a blood draw with a very high sodium and very low other values C. Abnormally low urine glucose values in a dataset D. Lab values from a blood draw with a very low sodium and very high other values
Answer: B Explanation: If a blood sample is drawn distal (downstream) from a saline infusion site, it may become contaminated with saline, leading to abnormal laboratory results. Saline contains a high concentration of sodium chloride, which artificially elevates sodium while diluting other blood components. Therefore, such samples would display: Very high sodium levels, and Abnormally low levels of other analytes (e.g., proteins, glucose, potassium). This abnormal pattern (option B) is a classic indicator of saline contamination. Per the GCDMP (Chapter: Data Validation and Cleaning), cross-variable consistency checks are critical for identifying biologically implausible patterns, such as this one, which indicate pre-analytical errors rather than true physiological changes. Hence, option B accurately describes the data signature of a contaminated blood draw. Reference (CCDM-Verified Sources): SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 6.2 “ Logical and Consistency Checks for Laboratory Data ICH E6(R2) GCP, Section 5.1.1 “ Data Quality and Biological Plausibility Checks FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 “ Detecting Laboratory Anomalies
Question # 9
What does RACI stand for?
A. Responsible, Accountable, Contribute, Input B. Recommend, Approve, Calibrate, Innovate C. Responsibility, Accountability, Consultation, Information D. Responsible, Accountable, Consulted, Informed
Answer: D Explanation:
RACI is a project management and governance framework used to define roles and responsibilities
within a project. Each letter represents a distinct role type:
Responsible (R): The person(s) who perform the work or execute the task.
Accountable (A): The individual ultimately answerable for the tasks completion and success (only
one per activity).
Consulted (C): Subject matter experts who provide input or guidance before decisions are made.
Informed (I): Individuals kept up to date on progress or outcomes but not directly involved in
execution.
The RACI model ensures clarity in ownership and accountability, preventing duplication of effort or
responsibility confusion. It is a key component of the GCDMP (Chapter: Project Management in Data
Management) for ensuring clear delegation and communication within clinical data management
teams.
Hence, option D is correct. Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management in Data Management, Section 5.1 “ Roles,
Responsibilities, and RACI Matrices
Project Management Institute (PMI) Framework “ Responsibility Assignment Matrices (RACI)
ICH E6(R2) GCP, Section 5.1.1 “ Defined Roles and Quality Oversight Responsibilities
Question # 10
A relational database has tables for PATIENT_DEMOGRAPHY and VITAL_SIGNS data collected during a
visit. The primary key for the VITAL_SIGNS table is a composite key that includes the unique patient
identifier, visit number, and vital signs parameter name. The two tables are joined on the patient
identifier. What will be the number of records in the result set?
A. One record per patient B. One record per visit C. One record per patient per visit per vital sign parameter D. One record per patient per visit
Answer: C Explanation:
In a relational database structure, each record in a table is uniquely identified by a primary key. In
this case, the VITAL_SIGNS table uses a composite primary key consisting of: Patient Identifier,
Visit Number, and
Vital Signs Parameter Name.
This means each record represents a unique measurement of a specific parameter (e.g., blood
pressure, pulse) for a patient at a specific visit.
When joining PATIENT_DEMOGRAPHY and VITAL_SIGNS tables on the patient identifier, the result set
will include one record for every combination of patient, visit, and parameter ” i.e., one record per
patient per visit per vital sign parameter.
Therefore, option C correctly describes the expected number of records.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.2 “ Primary and Foreign Key
Relationships in Relational Models
CDISC SDTM Implementation Guide, Section 5.3 “ Observation-Level Data Structures
ICH E6(R2) GCP, Section 5.5.3 “ Data Organization and Integration Principles
Question # 11
In a cross-functional team meeting, a monitor mentions performing source data verification (SDV) on
daily diary data entered by patients on mobile devices. Which of the following is the best response?
A. All diary data should be source data verified B. The diary data should not be source data verified C. Diary data to be source data verified should be selected using a risk-based approach D. Diary data to be source data verified should be randomly selected
Answer: C Explanation:
The best response is that diary data to be source data verified should be selected using a risk-based
approach.
According to the GCDMP (Chapter: Data Quality Assurance and Control) and FDA Guidance on RiskBased Monitoring (RBM), not all data require full SDV. Electronic patient-reported outcome (ePRO) or
mobile diary data are typically direct electronic source data (eSource) captured at the time of entry,
which already ensures authenticity and traceability.
A risk-based SDV approach focuses verification efforts on data critical to subject safety and primary
efficacy endpoints, as defined in the studys Risk Assessment Plan or Monitoring Plan. Random or full
verification of low-risk data (like diary compliance metrics) adds unnecessary effort and cost.
Thus, Option C aligns with current regulatory expectations and data management best practices.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and
Control, Section 7.3 “ Risk-Based Monitoring and SDV
ICH E6 (R2) Good Clinical Practice, Section 5.18 “ Risk-Based Quality Management
FDA Guidance for Industry: Oversight of Clinical Investigations ” A Risk-Based Approach to
Monitoring (2013)
Question # 12
There is a modification to the CRF and a sudden increase in the number of queries generated in the
EDC system. Which action is most likely to reduce the number of queries?
A. Make some of the existing edit checks manually B. Introduce a source data verification process C. Review the edit checks for correctness D. Have the monitor close the queries
Answer: C Explanation:
When a CRF modification leads to a sudden increase in EDC queries, the most likely cause is an error
or misconfiguration in the edit checks introduced during or after the change. Therefore, the first step
should be to review the edit checks for correctness.
The GCDMP (Chapter: Database Design and Validation) emphasizes that any database or CRF
modification should trigger retesting of affected validation rules. Incorrect logic, thresholds, or
missing conditional statements in automated edit checks can cause false or redundant queries,
leading to unnecessary data management burden and site frustration.
Manually handling edit checks (option A) or adding SDV (option B) does not address the root cause.
Having monitors close queries (option D) would mask the problem rather than resolve it.
Thus, the correct corrective measure is Option C ” review and validate the edit checks to ensure
proper functionality.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Validation,
Section: Section 5.5 “ Edit Check Testing and Review
ICH E6 (R2) GCP, Section 5.5.3 “ Validation and Change Control for Electronic Systems
FDA 21 CFR Part 11 “ System Validation and Change Documentation
Question # 13
A Data Manager receives an audit finding of three different instances of simultaneous log-ins to the
EDC system by the same site user. This was observed at three different sites. Which of the following
is the best long-term response to the audit finding?
A. Acquiring technical controls from the same or a different system vendor that prevent
simultaneous log-ins from the same user B. Refresher training for the offending users, re-communication of the binding nature of e-signatures to all users, routine monitoring for simultaneous log-ins from the same user C. Removing all access to the system until the situation is resolved D. Requesting that the sites fire the offending users for a HIPAA violation and increasing the monitoring for the offending sites
Answer: B Explanation:
The best long-term corrective and preventive action (CAPA) in this situation is a combination of user
re-training, communication, and routine monitoring ” as described in Option B.
According to the GCDMP (Chapter: Electronic Data Capture Systems) and FDA 21 CFR Part 11, user
credentials and electronic signatures in clinical systems are legally binding and must be used only by
the assigned individual. Simultaneous log-ins under the same credentials often indicate credential
sharing, a compliance violation that must be addressed through user education, reinforced security
policies, and ongoing system oversight.
While technical controls (option A) may be considered, behavioral and procedural reinforcement are
the first lines of defense. Options C and D are excessive and not aligned with proportional CAPA
practices.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC)
Systems, Section 7.1 “ User Access, Authentication, and Training FDA 21 CFR Part 11 “ Electronic Records and Electronic Signatures, Sections 11.10(i) and 11.200(a)
ICH E6 (R2) Good Clinical Practice, Section 5.5.3 “ Access Control and Audit Trail Requirements
Question # 14
A study team member suggests that data for a small, 50-patient, 2-year study can be entered and
cleaned in two weeks before lock. Which are important other considerations?
A. Processing the data in two weeks after the study is over would save money because the data manager would not be involved until the end B. Without the ability to capture the data electronically, the data cannot be checked or used to monitor and manage the study C. Processing the data in two weeks after the study is over would save money because the EDC system would only be needed for a month D. It would take more than two weeks to get second iteration queries generated and resolved
Answer: D Explanation:
The most critical consideration is that data cleaning is an iterative process, and completing all
necessary steps ” including query generation, site resolution, and second-pass validation ” cannot
realistically be accomplished within two weeks after study close.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Validation and
Cleaning), data cleaning must occur continuously throughout the study, not only at the end. Postdatabase
lock activities typically include running final validation checks, resolving outstanding
queries, performing reconciliation (e.g., SAEs, labs, coding), and conducting final quality review.
Even in small studies, query turnaround and response cycles from sites take time ” typically 2“4
weeks per iteration ” making a two-week total cleaning period unrealistic.
Therefore, Option D is correct: it would take more than two weeks to handle second-round (followup) queries and confirm final resolutions prior to database lock.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning,
Section: Section 5.4 “ Ongoing vs. End-of-Study Data Cleaning
ICH E6 (R2) Good Clinical Practice, Section 5.5.3 “ Data Quality and Timeliness
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations “ Data
Management and Cleaning
Question # 15
For a study, body mass index is calculated from weight and height. Which information is needed to
document the transformation?
A. Algorithm and algorithm version associated with the calculated value B. Algorithm associated with the calculated value C. User ID making the change and reason for change D. Algorithm documented in the Data Management Plan
Answer: A Explanation:
When derived or calculated variables (like Body Mass Index) are created, it is essential to document
the algorithm used and its version to ensure full data traceability and reproducibility.
According to GCDMP (Chapter: Database Design and Derived Data), every derived field must include
metadata describing:
The derivation algorithm (e.g., BMI = weight [kg] / height² [m²])
The version of the algorithm (if updates or revisions occur)
Any associated data sources or transformation rules This ensures consistent calculation across systems, prevents discrepancies during regulatory
submissions, and aligns with FDA and CDISC documentation expectations.
Option B lacks version control, which is critical for traceability. Option C describes audit trail data (not
derivation metadata), and option D refers to broader documentation, not specific algorithm
traceability.
Hence, option A (Algorithm and algorithm version associated with the calculated value) is the correct
and compliant answer.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Derived Data and Algorithms, Section 5.3 “ Documentation and Metadata
Requirements
ICH E6(R2) GCP, Section 5.5.3 “ Derived Data and Validation Traceability
FDA Guidance for Industry: Providing Regulatory Submissions in Electronic Format “ Data Definitions
(Define.xml)
Question # 16
The Scope of Work would answer which of the following information needs?
A. To determine the number of data transfers budgeted for a project B. To look up the date of the next clinical monitoring visit for a specific site C. To look up which visit PK samples are taken D. To find the name and contact information of a specific clinical data associate
Answer: A Explanation:
The Scope of Work (SOW) is a project management document that defines what services are
included in the work agreement between the sponsor and the CRO or vendor. It outlines
deliverables, responsibilities, timelines, and budget allocations.
According to the GCDMP (Chapter: Project Management in Data Management), the SOW includes
specifications such as:
The number and frequency of data transfers,
Database build and lock milestones,
Quality control deliverables, and
Resource allocation for data management tasks.
The SOW does not cover operational site-level details such as monitoring schedules (B), protocol
sampling details (C), or personnel contact lists (D).
Therefore, option A (number of data transfers budgeted for a project) correctly identifies a use case
directly addressed in the SOW.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management, Section 4.1 “ Scope of Work and Resource Planning
ICH E6(R2) GCP, Section 5.5 “ Sponsor Oversight and Data Management Responsibilities
PMI Project Management Framework “ Scope Definition and Deliverable Specifications
Question # 17
At a cross-functional study team meeting, a statistician suggests collecting blood gases electronically
through the existing continuous hemodynamic monitoring system at sites rather than having a person record the values every five minutes during the study procedure. Assuming that sending,
receiving, and integrating these data are possible, what is the best response?
A. Manual recording is preferred because healthcare devices are not validated to 21 CFR Part 11
standards B. Manual recording is preferred because the sites may forget to turn on the machine and lose data C. Electronic acquisition is preferable because more data points can be acquired D. Electronic acquisition is preferable because the chance for human error is removed
Answer: C Explanation:
Assuming the data transfer, integration, and validation processes are properly controlled and
compliant, electronic acquisition of clinical data from medical devices is preferred because it allows
more frequent and accurate data collection, leading to higher data resolution and integrity.
Per the GCDMP (Chapter: Technology and Data Integration), automated data collection minimizes
manual transcription and reduces latency in data capture, ensuring both efficiency and
completeness. While manual processes introduce human transcription errors and limit frequency,
continuous electronic data capture can record thousands of accurate, time-stamped measurements,
improving the studys analytical power.
However, option D slightly overstates the case ” human error is reduced, not entirely eliminated,
since setup, calibration, and integration still involve human oversight. Therefore, option C is the best
and most precise response, emphasizing the advantage of more robust and complete data capture.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Technology and Data Integration, Section 5.4 “ Automated Data Acquisition
and Validation
ICH E6(R2) GCP, Section 5.5.3 “ Validation of Computerized Systems and Electronic Data Sources
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 “ Direct
Data Capture from Instruments and Devices
Question # 18
An organization conducts over fifty studies per year. Currently each study is specified and set-up from
scratch. Which of the following organizational infrastructure options would streamline database setup
and study-to-study consistency?
A. Adopting an ODM compliant database system B. Maintaining a library of form or screen modules C. Improving the form or screen design process D. Implementing controlled terminology for adverse events
Answer: B Explanation:
To improve efficiency and ensure consistency across multiple studies, the most effective
infrastructure solution is to maintain a centralized library of standardized forms or screen modules
(e.g., CRF/eCRF templates).
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Database Design and
Build), using a form library allows reuse of validated data collection modules for commonly collected
domains such as demographics, adverse events, and vital signs. This reduces database setup time,
enhances uniformity in data definitions, and ensures alignment with standards such as CDISC CDASH
and SDTM.
While adopting ODM (A) provides standardized data exchange and interoperability, it does not
inherently reduce setup workload. Improving design processes (C) enhances efficiency but doesnt
guarantee consistency, and implementing controlled terminology (D) helps with coding
standardization, not database structure.
Therefore, option B ” maintaining a library of form or screen modules ” provides the most direct
and sustainable improvement for scalability and quality.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Database Design and Build, Section 5.3 “ Use of Standard Libraries and
Templates
CDISC CDASH Implementation Guide, Section 3.2 “ Reusable CRF Modules and Standardization
ICH E6(R2) GCP, Section 5.5.3 “ Standardization and Reuse in Data Collection Systems
Question # 19
Which of the following actions is particularly important in merging data from different trials?
A. Use of a common software platform B. Enrollment of investigative sites with similar patient populations C. Exclusion of studies that use a cross-over design D. Use of a common adverse event dictionary
Answer: D Explanation:
When merging data from different clinical trials, the use of a common adverse event (AE) dictionary
(such as MedDRA or WHO Drug) is essential to ensure consistency and comparability across datasets.
According to the GCDMP (Chapter: Standards and Data Mapping) and CDISC SDTM Implementation
Guide, data integration across studies requires standardized terminology for adverse events,
medications, and clinical outcomes. Using the same AE dictionary ensures that similar terms are
coded consistently, allowing accurate cross-study analysis, pooled summaries, and safety reporting.
A shared software platform (option A) is not necessary if data are mapped to standard formats (e.g.,
CDISC SDTM). Patient population similarity (option B) affects interpretation but not technical data
merging. Study design differences (option C) may influence statistical analysis but not data
integration mechanics.
Therefore, Option D “ Use of a common adverse event dictionary “ is the correct and most critical
action for consistent multi-study data integration.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Standards and Data Mapping,
Section: Section 5.1 “ Use of Standardized Coding Dictionaries
CDISC SDTM Implementation Guide, Section 4.3 “ Controlled Terminology and Cross-Study Integration
ICH E3 and E2B “ Clinical Data Standards and Safety Coding Requirements
Question # 20
Which mode of data entry is most commonly used in EDC systems?
A. Double entry B. Blind verification C. Single entry D. Third party compare
Answer: C Explanation:
The most common mode of data entry in Electronic Data Capture (EDC) systems is single data entry.
According to the GCDMP (Chapter: Electronic Data Capture Systems), EDC systems have built-in edit
checks, validation rules, and audit trails that ensure data accuracy and integrity at the point of entry.
These real-time validation capabilities make double data entry (a legacy practice from paper studies)
unnecessary.
EDC systems automatically verify data as they are entered by site staff, generating queries for
inconsistencies or out-of-range values immediately. Blind verification (option B) and third-party comparisons (option D) are not standard data entry modes but may be used for specialized
reconciliation or external data imports.
Thus, single data entry (Option C) is the industry standard approach, ensuring both efficiency and
compliance with FDA 21 CFR Part 11 and ICH E6 (R2) data integrity requirements.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Electronic Data Capture (EDC)
Systems, Section 5.4 “ Data Entry and Verification Processes
ICH E6 (R2) Good Clinical Practice, Section 5.5.3 “ Computerized Systems and Data Validation
FDA 21 CFR Part 11 “ Electronic Records and Electronic Signatures: Validation and Data Entry
Requirements
Question # 21
Which information should an auditee expect prior to an audit?
A. Auditor's credentials and certification number B. Corrective action requests C. Standard operating procedures D. Audit plan or agenda
Answer: D Explanation: Prior to an audit, the auditee should expect to receive an audit plan or agenda, which outlines the
scope, objectives, schedule, and logistics of the audit.
According to the GCDMP (Chapter: Quality Assurance and Audits), an audit plan ensures
transparency, preparation, and efficient execution. It typically includes details such as:
The audit scope and objectives,
The audit team members,
Documents or processes to be reviewed, and
The audit schedule and timeframe.
This allows the auditee to prepare the necessary records, staff, and facilities. While the auditors
credentials (option A) may be shared informally, they are not a regulatory requirement. Corrective
actions (option B) are outcomes of the audit, not pre-audit materials. Standard Operating Procedures
(option C) may be requested during the audit but are not provided in advance.
Thus, Option D “ Audit Plan or Agenda “ is the correct and compliant answer.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Quality Assurance and Audits,
Section: Section 6.1 “ Pre-Audit Planning and Communication
ICH E6 (R2) Good Clinical Practice, Section 5.19.3 “ Audit Procedures and Responsibilities
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations “ Section 8.1 “
Audit Preparation and Planning
Question # 22
When implementing a study utilizing an EDC application, it would be appropriate to use free text
fields for which of the following?
A. Urine sedimentation rate B. Adverse event verbatim term C. Date of birth D. Body Mass Index
Answer: B Explanation:
In Electronic Data Capture (EDC) systems, free text fields should be used only when a predefined list
of acceptable responses cannot accommodate the full variability of input data ” most notably for
Adverse Event (AE) verbatim terms.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data
Collection), AE verbatim terms are initially entered as free text by site staff to accurately capture the
investigators exact medical description of the event. These verbatim terms are later coded using
standardized dictionaries such as MedDRA during medical coding, ensuring both flexibility and
standardization in reporting.
Conversely, fields such as urine sedimentation rate (A), date of birth (C), and Body Mass Index (D)
require structured numeric or date formats to enable validation, range checks, and consistency
across datasets. Free text would compromise data integrity, accuracy, and validation efficiency for
these structured data elements.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection,
Section: Section 4.3 “ Use of Free Text and Coded Fields
ICH E6 (R2) Good Clinical Practice, Section 5.5.3 “ Data Structure and Validation
MedDRA Introductory Guide, Section 2.3 “ Verbatim Entry and Coding Requirements
Question # 23
A Data Manager is importing lab data for a study. The lab data and the associated audit trail is kept at
the central lab. What is necessary to maintain traceability of the transferred data at the Data
Manager's location?
A. Making changes only after data have been imported B. Maintaining a copy of the data as received C. Making changes only for exceptions D. Making changes only on the copy of the received data
Answer: B Explanation:
Maintaining traceability of external data imports (such as laboratory results) is a fundamental
principle of clinical data management. According to the GCDMP (Chapter: External Data Transfers
and Integration), Data Managers must retain an unaltered copy of the raw data exactly as received
from the vendor.
This archived version serves as a reference for:
Data provenance verification,
Audit trail review, and
Discrepancy resolution between vendor and study database.
Since the central lab maintains its own audit trail, the Data Managers responsibility is to preserve
the original data transmission file before applying transformations, merges, or validations.
Options A, C, and D describe procedural safeguards but do not meet the regulatory requirement of
traceable data lineage. Only option B (Maintaining a copy of the data as received) ensures
compliance with ICH E6(R2) and FDA 21 CFR Part 11 standards for data traceability and integrity.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers and Integration, Section 5.2 “ Data Traceability and
Version Control
ICH E6(R2) GCP, Section 5.5.3 “ Data Integrity and Source Data Verification
FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.4 “
Source Data Traceability and Archiving
Question # 24
The best example of a protocol compliance edit check is:
A. An edit check that fires when a visit date is outside the specified window B. An edit check that fires when a value is outside of the normal range for vital signs C. An edit check that fires when a field is left blank D. An edit check that fires when an invalid date is entered
Answer: A Explanation:
A protocol compliance edit check is designed to ensure that the data collected adheres to the specific
requirements defined in the study protocol, such as visit timing, procedure windows, and eligibility
criteria.
The example in option A ” an edit check that triggers when a visit date falls outside the protocolspecified
window ” directly verifies compliance with the study design. This type of check supports
real-time monitoring of protocol adherence, a critical quality and regulatory requirement under
GCDMP and ICH E6(R2).
Other options are examples of general data validation checks, not protocol compliance:
B: Ensures clinical plausibility (data range check).
C: Ensures completeness (missing data check).
D: Ensures format correctness (system validation check).
Thus, option A best represents a protocol compliance edit check, confirming that collected data
conform to the visit schedule defined in the protocol.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 5.4 “ Protocol Compliance Edit Checks
ICH E6(R2) GCP, Section 5.1.1 “ Quality Management and Compliance Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 “ Edit
Check Design and Validation
Question # 25
Which information is required by most systems to specify data entry screens?
A. User role, access level, and permissions B. Data type, prompt, and response format C. Page number and total number of pages D. Help text, review parameters, and answers
Answer: B Explanation:
When designing or configuring data entry screens within an Electronic Data Capture (EDC) system,
three critical components are required for each field:
Data Type “ Defines the nature of the data (e.g., text, numeric, date).
Prompt “ The label or question displayed to the user.
Response Format “ Specifies how the user enters or selects data (e.g., free text, drop-down,
checkbox).
According to the GCDMP (Chapter: EDC Systems and Database Design), these three attributes form the logical data structure required to build and validate data entry interfaces. They ensure
consistency in how information is captured, displayed, and validated during data entry.
While user roles (A) and help text (D) are system-level configurations, not field-level specifications,
page numbers (C) relate to printed CRFs rather than digital data screens.
Therefore, option B (Data type, prompt, and response format) correctly identifies the essential
information needed to define data entry screens.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: EDC Systems and Database Design, Section 4.3 “ Screen Design
Specifications
CDISC CDASH Implementation Guide, Section 3.2 “ Data Field Attributes
ICH E6(R2) GCP, Section 5.5.3 “ Data Capture and Input Standards
Feedback That Matters: Reviews of Our SCDM CCDM Dumps
